1065-A Molecular Blueprint for V3-Glycan HIV Vaccine Design

Researchers have developed an innovative animal model using rhesus macaques to overcome a long-standing hurdle in HIV-1 vaccine design. By utilizing a specifically engineered virus called SHIV.5MUT, the team successfully induced broadly neutralizing antibodies (bNAbs) that target the V3-glycan epitope, a feat previously difficult to achieve in outbred species. This process occurs through a two-step mechanism where an initial wave of antibodies forces the virus to evolve shortened V1 loops, which subsequently exposes the target site to prime the immune system. The study highlights that these macaque-derived bNAbs are structurally and genetically similar to human antibodies, suggesting that the developmental pathways observed can serve as a reliable molecular blueprint. These findings provide a new benchmark for iterative vaccine design, demonstrating that potent and diverse immune responses can be consistently elicited through epitope-focused strategies. Consequently, the research supports the use of modified immunogens in future human clinical trials to generate broad protection against global HIV-1 strains.

References:

• Skelly A N, Gristick H B, Li H, et al. Induction of broadly neutralizing HIV antibodies by a two-step mechanism informs vaccine design[J]. Science, 2026: eaec6396.